English
Insider transactions
EDGARCULLINAN THERAPEUTICS, INC.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-18.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 29 transactions, 169,912 shares
- Sum of shares × price per share: 2,558,835.7
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 60
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-05 Filed 2026-11-06 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,805 | 4.30 | 16,361.5Derived: shares × price per share. Exact value 16361.50. | 162,649 | Direct (D) | Yes | — | Open filing 0001193125-26-452004 Read from the filing’s XML Dispute this row |
| 2026-11-05 Filed 2026-11-06 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,000 | 12.36 | 49,440Derived: shares × price per share. Exact value 49440.00. | 158,649 | Direct (D) | Yes | F1
| Open filing 0001193125-26-452004 Read from the filing’s XML Dispute this row |
| 2026-11-05 Filed 2026-11-06 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 3,805 | 0 | — | 75,182 | Direct (D) | Yes | F2
| Open filing 0001193125-26-452004 Read from the filing’s XML Dispute this row |
| 2026-09-08 Filed 2026-09-10 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 4,000 | 4.30 | 17,200Derived: shares × price per share. Exact value 17200.00. | 166,844 | Direct (D) | Yes | — | Open filing 0001193125-26-387381 Read from the filing’s XML Dispute this row |
| 2026-09-08 Filed 2026-09-10 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 8,000 | 21.57 | 172,560Derived: shares × price per share. Exact value 172560.00. | 158,844 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-387381 Read from the filing’s XML Dispute this row |
| 2026-09-08 Filed 2026-09-10 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 4,000 | 0 | — | 78,987 | Direct (D) | Yes | F3
| Open filing 0001193125-26-387381 Read from the filing’s XML Dispute this row |
| 2026-08-13 Filed 2026-08-14 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 30,000 | 4.30 | 129,000Derived: shares × price per share. Exact value 129000.00. | 192,844 | Direct (D) | Yes | — | Open filing 0001193125-26-352523 Read from the filing’s XML Dispute this row |
| 2026-08-13 Filed 2026-08-14 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 30,000 | 20.26 | 607,800Derived: shares × price per share. Exact value 607800.00. | 162,844 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-352523 Read from the filing’s XML Dispute this row |
| 2026-08-13 Filed 2026-08-14 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 30,000 | 0 | — | 82,987 | Direct (D) | Yes | F3
| Open filing 0001193125-26-352523 Read from the filing’s XML Dispute this row |
| 2026-07-06 Filed 2026-07-07 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 4,000 | 4.30 | 17,200Derived: shares × price per share. Exact value 17200.00. | 170,844 | Direct (D) | Yes | — | Open filing 0001193125-26-297605 Read from the filing’s XML Dispute this row |
| 2026-07-06 Filed 2026-07-07 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 8,000 | 17.82 | 142,560Derived: shares × price per share. Exact value 142560.00. | 162,844 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-297605 Read from the filing’s XML Dispute this row |
| 2026-07-06 Filed 2026-07-07 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 4,000 | 0 | — | 112,987 | Direct (D) | Yes | F3
| Open filing 0001193125-26-297605 Read from the filing’s XML Dispute this row |
| 2026-06-30 Filed 2026-07-02 | SUMER JACQUELYN L Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,470 | 8.60 | 21,242Derived: shares × price per share. Exact value 21242.00. | 130,559 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-294869 Read from the filing’s XML Dispute this row |
| 2026-06-30 Filed 2026-07-02 | Fenton Mary Kay Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,541 | 8.60 | 13,252.6Derived: shares × price per share. Exact value 13252.60. | 127,921 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-294863 Read from the filing’s XML Dispute this row |
| 2026-06-16 Filed 2026-06-18 | Rosenberg Anthony Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,319 | 0 | — | 25,319 | Direct (D) | No | F1
| Open filing 0001193125-26-276060 Read from the filing’s XML Dispute this row |
| 2026-06-16 Filed 2026-06-18 | Doyle Mittie Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 21,781 | 0 | — | 21,781 | Direct (D) | No | F1
| Open filing 0001193125-26-276054 Read from the filing’s XML Dispute this row |
| 2026-06-16 Filed 2026-06-18 | Meek David D. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,319 | 0 | — | 25,319 | Direct (D) | No | F1
| Open filing 0001193125-26-276059 Read from the filing’s XML Dispute this row |
| 2026-06-16 Filed 2026-06-18 | Allen Andrew R Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 21,781 | 0 | — | 21,781 | Direct (D) | No | F1
| Open filing 0001193125-26-276056 Read from the filing’s XML Dispute this row |
| 2026-06-16 Filed 2026-06-18 | Webster Stephen W Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,319 | 0 | — | 25,319 | Direct (D) | No | F1
| Open filing 0001193125-26-276057 Read from the filing’s XML Dispute this row |
| 2026-06-16 Filed 2026-06-18 | Thistle Mary Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,319 | 0 | — | 25,319 | Direct (D) | No | F1
| Open filing 0001193125-26-276055 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-06 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 4,000 | 4.30 | 17,200Derived: shares × price per share. Exact value 17200.00. | 174,844 | Direct (D) | Yes | — | Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-06 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 7,800 | 14.60 | 113,880Derived: shares × price per share. Exact value 113880.00. | 167,044 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-06 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 200 | 15.58 | 3,116Derived: shares × price per share. Exact value 3116.00. | 166,844 | Direct (D) | Yes | F1, F3
| Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-06 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 4,000 | 0 | — | 116,987 | Direct (D) | Yes | F4
| Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row |
| 2026-03-05 Filed 2026-03-09 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 4,000 | 4.30 | 17,200Derived: shares × price per share. Exact value 17200.00. | 178,844 | Direct (D) | Yes | — | Open filing 0001193125-26-098781 Read from the filing’s XML Dispute this row |
| 2026-03-05 Filed 2026-03-09 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 8,000 | 15.68 | 125,440Derived: shares × price per share. Exact value 125440.00. | 170,844 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-098781 Read from the filing’s XML Dispute this row |
| 2026-03-05 Filed 2026-03-09 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 4,000 | 0 | — | 120,987 | Direct (D) | Yes | F3
| Open filing 0001193125-26-098781 Read from the filing’s XML Dispute this row |
| 2026-02-25 Filed 2026-02-26 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,780 | 14.14 | 25,169.2Derived: shares × price per share. Exact value 25169.20. | 174,844 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-077259 Read from the filing’s XML Dispute this row |
| 2026-02-24 Filed 2026-02-25 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,601 | 14.47 | 52,106.47Derived: shares × price per share. Exact value 52106.47. | 176,624 | Direct (D) | Yes | F3
| Open filing 0001193125-26-072002 Read from the filing’s XML Dispute this row |
| 2026-02-24 Filed 2026-02-25 | SUMER JACQUELYN L Officer: Chief Legal Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,601 | 14.47 | 52,106.47Derived: shares × price per share. Exact value 52106.47. | 128,089 | Direct (D) | No | F1
| Open filing 0001193125-26-071997 Read from the filing’s XML Dispute this row |
| 2026-02-24 Filed 2026-02-25 | Jones Jeffrey Alan Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,582 | 14.47 | 66,301.54Derived: shares × price per share. Exact value 66301.54. | 159,968 | Direct (D) | No | F1
| Open filing 0001193125-26-072000 Read from the filing’s XML Dispute this row |
| 2026-02-24 Filed 2026-02-25 | AHMED NADIM Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 13,515 | 14.47 | 195,562.05Derived: shares × price per share. Exact value 195562.05. | 390,803 | Direct (D) | No | F1
| Open filing 0001193125-26-072001 Read from the filing’s XML Dispute this row |
| 2026-02-23 Filed 2026-02-25 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,752 | 13.99 | 24,510.48Derived: shares × price per share. Exact value 24510.48. | 180,225 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-072002 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | Jones Jeffrey Alan Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,982 | 13.62 | 67,854.84Derived: shares × price per share. Exact value 67854.84. | 164,550 | Direct (D) | No | F1
| Open filing 0001193125-26-064257 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | Fenton Mary Kay Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,398 | 13.62 | 59,900.76Derived: shares × price per share. Exact value 59900.76. | 126,380 | Direct (D) | No | F1
| Open filing 0001193125-26-064261 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | SUMER JACQUELYN L Officer: Chief Legal Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,742 | 13.62 | 50,966.04Derived: shares × price per share. Exact value 50966.04. | 131,690 | Direct (D) | No | F1
| Open filing 0001193125-26-064255 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,742 | 13.62 | 50,966.04Derived: shares × price per share. Exact value 50966.04. | 181,977 | Direct (D) | Yes | F1
| Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 8,000 | 4.30 | 34,400Derived: shares × price per share. Exact value 34400.00. | 189,977 | Direct (D) | Yes | — | Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 8,000 | 14.30 | 114,400Derived: shares × price per share. Exact value 114400.00. | 181,977 | Direct (D) | Yes | F2
| Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | Michaelson Jennifer Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 8,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 124,987 | Direct (D) | Yes | F3
| Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-02-23 | AHMED NADIM Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,381 | 13.62 | 223,109.22Derived: shares × price per share. Exact value 223109.22. | 404,318 | Direct (D) | No | F1
| Open filing 0001193125-26-064254 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | Jones Jeffrey Alan Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001193125-26-059640 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | AHMED NADIM Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 828,000 | 0 | — | 828,000 | Direct (D) | No | F1
| Open filing 0001193125-26-059639 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | Michaelson Jennifer Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 57,500 | 0 | — | 185,719 | Direct (D) | No | F1
| Open filing 0001193125-26-059636 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | Michaelson Jennifer Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 115,000 | 0 | — | 115,000 | Direct (D) | No | F2
| Open filing 0001193125-26-059636 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | Savill Corrine Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 175,000 | 0 | — | 175,000 | Direct (D) | No | F1
| Open filing 0001193125-26-059638 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | Fenton Mary Kay Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 68,750 | 0 | — | 130,778 | Direct (D) | No | F1
| Open filing 0001193125-26-059637 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | Fenton Mary Kay Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 137,500 | 0 | — | 137,500 | Direct (D) | No | F2
| Open filing 0001193125-26-059637 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-02-19 | SUMER JACQUELYN L Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 230,000 | 0 | — | 230,000 | Direct (D) | No | F1
| Open filing 0001193125-26-059641 Read from the filing’s XML Dispute this row |
| 2026-02-12 Filed 2026-02-13 | Michaelson Jennifer Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 416 | 12.03 | 5,004.48Derived: shares × price per share. Exact value 5004.48. | 128,219 | Direct (D) | No | F1
| Open filing 0001193125-26-051700 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.
Showing 1–50 of 191
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | 9,721,081 SH | 149,218,593 dollars | Lower by 10,260 Prior quarter: 9,731,341 | Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row |
| Lynx1 Capital Management LP Partly reported under another manager | 8,963,500 SH | 137,589,725 dollars | Unchanged Prior quarter: 8,963,500 | Open filing 0001910456-26-000007 Filed 2026-11-16 Dispute this row |
| BVF INC/IL Partly reported under another manager | 5,750,683 SH | 88,272,984 dollars | Unchanged Prior quarter: 5,750,683 | Open filing 0000921895-26-003162 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 5,319,313 SH | 81,651,455 dollars | Higher by 86,547 Prior quarter: 5,232,766 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager | 4,091,640 SH | 62,807 dollars | Higher by 265,690 Prior quarter: 3,825,950 | Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row |
| Kynam Capital Management, LP | 3,114,132 SH | 47,801,926 dollars | Unchanged Prior quarter: 3,114,132 | Open filing 0001907884-26-000017 Filed 2026-11-16 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,641,522 SH | 40,547,363 dollars | Higher by 27,456 Prior quarter: 2,614,066 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 2,604,105 SH | 39,973,012 dollars | Lower by 1,064,522 Prior quarter: 3,668,627 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| RTW INVESTMENTS, LP | 2,364,347 SH | 36,292,726 dollars | Unchanged Prior quarter: 2,364,347 | Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row |
| Siren, L.L.C. Partly reported under another manager | 1,793,410 SH | 27,528,844 dollars | Lower by 100,000 Prior quarter: 1,893,410 | Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 1,448,600 SH | 22,240,987 dollars | Lower by 98,709 Prior quarter: 1,547,309 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Blue Owl Capital Holdings LP Partly reported under another manager | 1,399,899 SH | 21,488,450 dollars | Lower by 139,865 Prior quarter: 1,539,764 | Open filing 0001193125-26-459653 Filed 2026-11-13 Dispute this row |
| Venrock Adviser, LLC | 1,379,965 SH | 21,182,463 dollars | Unchanged Prior quarter: 1,379,965 | Open filing 0001615982-26-000019 Filed 2026-11-16 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 1,084,765 SH | 16,650,457 dollars | Higher by 38,071 Prior quarter: 1,046,694 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 988,963 SH | 15,180,582 dollars | Lower by 12,635 Prior quarter: 1,001,598 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| Elmind Capital, LP | 962,792 SH | 14,778,857 dollars | Higher by 272,792 Prior quarter: 690,000 | Open filing 0001013594-26-001197 Filed 2026-11-16 Dispute this row |
| BOOTHBAY FUND MANAGEMENT, LLC | 953,126 SH | 14,630,484 dollars | Lower by 129,485 Prior quarter: 1,082,611 | Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row |
| Affinity Asset Advisors, LLC | 875,760 SH | 13,442,916 dollars | Unchanged Prior quarter: 875,760 | Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row |
| Fisher Asset Management, LLC Partly reported under another manager | 800,961 SH | 12,294,750 dollars | Higher by 764,963 Prior quarter: 35,998 | Open filing 0000850529-26-000009 Filed 2026-11-06 Dispute this row |
| BOONE CAPITAL MANAGEMENT LLC | 690,814 SH | 10,603,995 dollars | Lower by 13,628 Prior quarter: 704,442 | Open filing 0001214659-26-014343 Filed 2026-11-16 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 644,639 SH | 9,895,209 dollars | Higher by 15,604 Prior quarter: 629,035 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 643,491 SH | 9,877,587 dollars | Lower by 95,250 Prior quarter: 738,741 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| TWIN FOCUS CAPITAL PARTNERS, LLC | 595,489 SH | 9,140,756 dollars | Unchanged Prior quarter: 595,489 | Open filing 0001172661-26-005036 Filed 2026-11-13 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 558,159 SH | 8,567,740 dollars | Lower by 12,921 Prior quarter: 571,080 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 506,077 SH | 7,768,282 dollars | Higher by 42,043 Prior quarter: 464,034 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| AQR CAPITAL MANAGEMENT LLC Partly reported under another manager | 498,566 SH | 7,652,989 dollars | Lower by 82,772 Prior quarter: 581,338 | Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row |
| Boxer Capital Management, LLC | 450,000 SH | 6,907,500 dollars | Not in the prior quarter’s filings read | Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 415,972 SH | 6,385,170 dollars | Lower by 94,353 Prior quarter: 510,325 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| TCG Crossover Management, LLC | 406,786 SH | 6,244,165 dollars | Unchanged Prior quarter: 406,786 | Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row |
| DEUTSCHE BANK AG\ Partly reported under another manager | 377,837 SH | 5,799,798 dollars | Lower by 5,003 Prior quarter: 382,840 | Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 376,124 SH | 5,773,503 dollars | Higher by 12,988 Prior quarter: 363,136 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| FMR LLC Partly reported under another manager | 336,451 SH | 5,164,516 dollars | Higher by 96,336 Prior quarter: 240,115 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| GREAT POINT PARTNERS LLC Partly reported under another manager | 300,000 SH | 4,605,000 dollars | Unchanged Prior quarter: 300,000 | Open filing 0001172661-26-005345 Filed 2026-11-16 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 290,011 SH | 4,451,669 dollars | Lower by 36,800 Prior quarter: 326,811 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| Connor, Clark Lunn Investment Management Ltd. | 286,096 SH | 4,391,574 dollars | Lower by 6,404 Prior quarter: 292,500 | Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row |
| Invesco Ltd. Partly reported under another manager | 283,144 SH | 4,346,261 dollars | Higher by 139,592 Prior quarter: 143,552 | Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 273,316 SH | 4,162,602 dollars | Lower by 9,315 Prior quarter: 282,631 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager | 262,713 SH | 4,032,645 dollars | Higher by 97,997 Prior quarter: 164,716 | Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row |
| Bleichroeder LP | 250,000 SH | 3,837,500 dollars | Unchanged Prior quarter: 250,000 | Open filing 0001420506-26-002662 Filed 2026-11-13 Dispute this row |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Put Partly reported under another manager | 240,700 SH | 3,694,745 dollars | Higher by 204,700 Prior quarter: 36,000 | Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager | 236,200 SH | 3,625,670 dollars | Higher by 149,600 Prior quarter: 86,600 | Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 229,203 SH | 3,518,266 dollars | Lower by 19,424 Prior quarter: 248,627 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 219,719 SH | 3,372,687 dollars | Lower by 52,862 Prior quarter: 272,581 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| JANE STREET GROUP, LLC Option: Put Partly reported under another manager | 217,500 SH | 3,338,625 dollars | Higher by 180,800 Prior quarter: 36,700 | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| Trexquant Investment LP Partly reported under another manager | 209,314 SH | 3,212,970 dollars | Higher by 57,151 Prior quarter: 152,163 | Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Option: Put Partly reported under another manager | 201,600 SH | 3,094,560 dollars | Higher by 136,400 Prior quarter: 65,200 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| Apis Capital Advisors, LLC | 192,000 SH | 2,947,200 dollars | Higher by 112,000 Prior quarter: 80,000 | Open filing 0001420506-26-002720 Filed 2026-11-13 Dispute this row |
| MOORE CAPITAL MANAGEMENT, LP | 181,306 SH | 2,783,047 dollars | Lower by 8,640 Prior quarter: 189,946 | Open filing 0001448574-26-000004 Filed 2026-11-16 Dispute this row |
| BARCLAYS PLC Partly reported under another manager | 177,595 SH | 2,726,082 dollars | Higher by 33,650 Prior quarter: 143,945 | Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row |
| HighVista Strategies LLC | 173,895 SH | 2,669,289 dollars | Not in the prior quarter’s filings read | Open filing 0001172661-26-004983 Filed 2026-11-13 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Sixth Street Partners Management Company, L.P. 464,034 SH
- PERCEPTIVE ADVISORS LLC 426,478 SH
- ADAGE CAPITAL PARTNERS GP, L.L.C. 238,000 SH
- Assenagon Asset Management S.A. 123,364 SH
- Y-Intercept (Hong Kong) Ltd 80,648 SH
- Point72 Asset Management, L.P. 75,009 SH
- MARSHALL WACE, LLP 66,051 SH
- Soleus Capital Management, L.P. 50,000 SH
- ALGERT GLOBAL LLC 36,851 SH
- Verdad Advisers, LP 28,987 SH
- ExodusPoint Capital Management, LP 28,537 SH
- OPTIMIZE FINANCIAL INC. 28,061 SH
- Sound Capital Solutions LLC 28,061 SH
- NEW YORK STATE COMMON RETIREMENT FUND 21,218 SH
- MILLENNIUM MANAGEMENT LLC 20,000 SH
- Qube Research Technologies Ltd 19,936 SH
- SG Americas Securities, LLC 19,058 SH
- Jupiter Topco LLC 18,528 SH
- TWO SIGMA SECURITIES, LLC 15,220 SH
- AXQ CAPITAL, LP 14,935 SH
- INTECH INVESTMENT MANAGEMENT LLC 12,418 SH
- EntryPoint Capital, LLC 11,556 SH
- Curated Wealth Partners LLC 10,000 SH
- Quantbot Technologies LP 2,911 SH
- Integrated Wealth Concepts LLC 1,349 SH
- Pacer Advisors, Inc. 1,104 SH
- Optiver Holding B.V. 140 SH
- Wealth Enhancement Trust Services, Inc. 79 SH
- NATIONAL BANK OF CANADA /FI/ 23 SH
- Basecamp Wealth Advisors LLC 14 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| STATE STREET CORPORATION COMMON STOCK | 4 | 2,604,105.00 | 09/30/2026 Filed 2026-11-10 | SCHEDULE 13G | Open filing 0000093751-26-000639 Dispute this row |
| BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share | 5.7 | 3,711,284.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BVF I GP LLC Common Stock, par value $0.0001 per share | 5.7 | 3,711,284.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share | 3.5 | 2,269,166.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BVF II GP LLC Common Stock, par value $0.0001 per share | 3.5 | 2,269,166.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| Biotechnology Value Trading Fund OS LP Common Stock, par value $0.0001 per share | 0.6 | 400,861.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BVF Partners OS Ltd. Common Stock, par value $0.0001 per share | 0.6 | 400,861.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BVF GP HOLDINGS LLC Common Stock, par value $0.0001 per share | 9.2 | 5,980,450.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BVF PARTNERS L P/IL Common Stock, par value $0.0001 per share | 9.99 | 6,491,123.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| BVF INC/IL Common Stock, par value $0.0001 per share | 9.99 | 6,491,123.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| LAMPERT MARK N Common Stock, par value $0.0001 per share | 9.99 | 6,491,123.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 8 | Open filing 0000921895-26-002166 Dispute this row |
| T. Rowe Price Associates, Inc. COMMON STOCK | 6.2 | 3,825,950 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G | Open filing 0000080255-26-000574 Dispute this row |
| STATE STREET CORPORATION COMMON STOCK | 6 | 3,668,627.00 | 06/30/2026 Filed 2026-08-07 | SCHEDULE 13G | Open filing 0000093751-26-000446 Dispute this row |
| BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share | 5.8 | 3,551,482.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BVF I GP LLC Common Stock, par value $0.0001 per share | 5.8 | 3,551,482.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share | 3.7 | 2,272,849.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BVF II GP LLC Common Stock, par value $0.0001 per share | 3.7 | 2,272,849.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| Biotechnology Value Trading Fund OS LP Common Stock, par value $0.0001 per share | 0.4 | 224,641.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BVF Partners OS Ltd. Common Stock, par value $0.0001 per share | 0.4 | 224,641.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BVF GP HOLDINGS LLC Common Stock, par value $0.0001 per share | 9.4 | 5,824,331.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BVF PARTNERS L P/IL Common Stock, par value $0.0001 per share | 9.99 | 6,161,469.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| BVF INC/IL Common Stock, par value $0.0001 per share | 9.99 | 6,161,469.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| LAMPERT MARK N Common Stock, par value $0.0001 per share | 9.99 | 6,161,469.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 7 | Open filing 0000921895-26-001387 Dispute this row |
| The Vanguard Group Common Stock | 0 | 0 | 03/13/2026 Filed 2026-03-26 | SCHEDULE 13G/AAmendment 1 | Open filing 0000102909-26-001005 Dispute this row |
| Kynam Capital Management, LP Common Stock, par value $0.0001 per share | 5.27 | 3,114,132 | 12/31/2025 Filed 2026-03-04 | SCHEDULE 13G | Open filing 0001907884-26-000005 Dispute this row |
| Kynam Capital Management GP, LLC Common Stock, par value $0.0001 per share | 5.27 | 3,114,132 | 12/31/2025 Filed 2026-03-04 | SCHEDULE 13G | Open filing 0001907884-26-000005 Dispute this row |
| Yue Tang Common Stock, par value $0.0001 per share | 5.27 | 3,114,132 | 12/31/2025 Filed 2026-03-04 | SCHEDULE 13G | Open filing 0001907884-26-000005 Dispute this row |
| BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share | 5.6 | 3,302,376.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BVF I GP LLC Common Stock, par value $0.0001 per share | 5.6 | 3,302,376.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share | 3.8 | 2,271,662.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BVF II GP LLC Common Stock, par value $0.0001 per share | 3.8 | 2,271,662.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| Biotechnology Value Trading Fund OS LP Common Stock, par value $0.0001 per share | 0.4 | 224,641.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BVF Partners OS Ltd. Common Stock, par value $0.0001 per share | 0.4 | 224,641.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BVF GP HOLDINGS LLC Common Stock, par value $0.0001 per share | 9.4 | 5,574,038.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BVF PARTNERS L P/IL Common Stock, par value $0.0001 per share | 9.99 | 5,918,481.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| BVF INC/IL Common Stock, par value $0.0001 per share | 9.99 | 5,918,481.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| LAMPERT MARK N Common Stock, par value $0.0001 per share | 9.99 | 5,918,481.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 6 | Open filing 0000921895-26-000457 Dispute this row |
| The Vanguard Group Common Stock | 5.58 | 3,298,504 | 12/31/2025 Filed 2026-01-30 | SCHEDULE 13G | Open filing 0000102909-26-000065 Dispute this row |
| Lynx1 Capital Management LP Common Stock, par value $0.0001 per share | 14.5 | 8,549,084.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13G/AAmendment 1 | Open filing 0000902664-25-004377 Dispute this row |
| Weston Nichols Common Stock, par value $0.0001 per share | 14.5 | 8,549,084.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13G/AAmendment 1 | Open filing 0000902664-25-004377 Dispute this row |
| Citadel Advisors LLC Common Stock, par value $0.0001 per share (the "Shares") | 3.1 | 1,841,079.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| Citadel Advisors Holdings LP Common Stock, par value $0.0001 per share (the "Shares") | 3.1 | 1,841,079.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| Citadel GP LLC Common Stock, par value $0.0001 per share (the "Shares") | 3.1 | 1,841,079.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| Citadel Securities LLC Common Stock, par value $0.0001 per share (the "Shares") | 0.3 | 147,828.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| Citadel Securities Group LP Common Stock, par value $0.0001 per share (the "Shares") | 0.3 | 147,828.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| Citadel Securities GP LLC Common Stock, par value $0.0001 per share (the "Shares") | 0.3 | 147,828.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| Kenneth Griffin Common Stock, par value $0.0001 per share (the "Shares") | 3.4 | 1,988,907.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-112463 Dispute this row |
| LYNX1 CAPITAL MANAGEMENT LP Common Stock, par value $0.0001 per share | 9.8 | 5,766,090.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0000902664-25-004966 Dispute this row |
| WESTON NICHOLS Common Stock, par value $0.0001 per share | 9.8 | 5,766,090.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0000902664-25-004966 Dispute this row |
| Deerfield Mgmt, L.P. Common Stock | 4.95 | 2,927,013.00 | 09/30/2025 Filed 2025-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193805-25-001585 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,316,298 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 17,836 |
| 2016 | 211,665 |
| 2017 | 207,865 |
| 2018 | 202,770 |
| 2019 | 215,153 |
| 2020 | 144,184 |
| 2021 | 224,474 |
| 2022 | 158,941 |
| 2023 | 199,811 |
| 2024 | 209,823 |
| 2025 | 235,520 |
| 2026 | 260,174 |
Filings made before the SEC required XML are listed, not extracted.